Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Oncolys to Codevelop COVID-19 Med with Shin Nippon Biomedical
April 21, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
- Bayer’s Japan Sales Sag 5%, but Targets Reached in 2020
April 19, 2021
- Kobayashi Kako Chief Sorry for Fake Application Documents; Third-Party Report Reveals New Problems
April 19, 2021
- Takeda, Nihon Pharm to Discuss Integration of Plasma Businesses
April 19, 2021
- Fujifilm Holdings Aims to Ring Up Healthcare Sales of 860 Billion Yen in FY2023: 3-Year Biz Plan
April 19, 2021
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
- Towa Files Additional Request for Livalo Patent Invalidity in December 2020
April 16, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Rohto Licenses COVID-19 Drug Candidate from Japan Biotech
April 15, 2021
- Ono Files Opdivo for Cancer of Unknown Primary in Japan
April 15, 2021
- Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Otsuka, Lundbeck to Carry On Multinational PIII of Brexpiprazole for Agitation in Alzheimer’s
April 14, 2021
- Urovant’s OAB Med Gemtesa Now Available in US
April 14, 2021
- Kobayashi Kako Recalling 4 Mesalazine Products due to OOS
April 14, 2021
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Nipro Gets Approval of Seven-Dose Syringe for Pfizer COVID-19 Vaccine
April 13, 2021
- MSD Files Keytruda for RCC in Combo Therapy with Lenvima
April 13, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…